Navigation Links
Avalon Pharmaceuticals names lead development candidate in beta-catenin inhibitor program
Date:6/26/2008

Germantown, MD, June 26, 2008 -- Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), announced today the nomination of AVN316 as a lead clinical development candidate in its Beta-catenin Pathway Inhibitor program. This novel compound inhibits the Beta-catenin pathway and is a potent inducer of cancer cell death. The Company plans to begin clinical testing of AVN316 in patients in 2009.

Beta-catenin is one of the most commonly activated cancer pathways and is known to play a key role in the initiation and progression of cancer. The Beta-catenin pathway is upregulated in a large number of different cancer types, in particular colon cancer, where it has been estimated to be abnormally activated in at least 90 percent of cases.

"The biological complexity and the classically intractable nature of the beta-catenin protein have prevented this pathway from being effectively targeted by conventional drug discovery techniques, despite the efforts of numerous pharmaceutical companies," stated Kenneth Carter, Ph.D., President and CEO of Avalon Pharmaceuticals, Inc. "We are very pleased to name AVN316 as the lead compound for this intractable target, which we believe provides validation for our unique drug discovery platform, AvalonRx."

Using AvalonRx, the Company identified several chemical compounds series that inhibit beta-catenin function. One family of structurally distinct chemical compounds potently down-regulate the Beta-catenin pathway by reducing beta-catenin protein levels. This lead compound series (of which AVN316 is a member) decreases the beta-catenin protein levels in cancer cells and xenograft tumors, induces biomarkers of Beta-catenin pathway inhibition, and inhibits tumor growth. AVN316 was chosen from the series for its potency and tumor growth inhibition properties in animal models of human disease. Near-term activities with AVN316 include toxicology studies and large-scale manufacturing in preparation for IND submission to the FDA.


'/>"/>

Contact: Kate Gormley
kgormley@dorland.com
215-928-2720
Dorland Global Public Relations
Source:Eurekalert

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , ... February 24, 2017 , ... The California ... conference convening academic faculty engaged in or interested in palliative care education and research. ... will be held in North County San Diego on Sept. 28 and 29, 2017, ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... marketing services, which specializes in thought leadership , media relations, social media, ... and services that will be powered through Act-On, an intuitive marketing automation platform. ...
(Date:2/23/2017)... ... February 23, 2017 , ... The 89th Academy Awards ... of the 2016 National Education Policy Center Bunkum Award. We invite you to enjoy ... , This year’s Bunkum winner is the Center for American Progress (CAP), for its ...
(Date:2/23/2017)... ... February 23, 2017 , ... Hamlin Dental Group and Dr. ... are sponsoring a raffle. Throughout the month of February, patients who visit Hamlin Dental ... card for a dinner for two at the Cheesecake Factory. , Tickets are ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing LLC ... converge and explore the world from different perspectives. By providing a place for ... gain understanding, increase empathy, and find greater happiness. , "Our approach to ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis ... the global Autism Spectrum Disorder market. The research answers the ... drugs marketed for Autism Spectrum Disorder and their clinical attributes? How ...
(Date:2/23/2017)... Medical, Inc. (NASDAQ: CGNT), a medical device company that ... urology market, will release financial results for the fourth ... the market open on Thursday, March 9, 2017. ... and webcast to discuss its financial results the same ... Eastern Time (10:00 a.m. Central Time). Darin Hammers ...
(Date:2/23/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - 2016, provides ... research answers the following questions: What are ... they positioned in the Global Menopause market? What are ...
Breaking Medicine Technology: